Medmira Inc (TSE:MIR) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medmira Inc. reports a significant corporate milestone with the US FDA 510(k) clearance for its Reveal G4 Rapid HIV-1/2 antibody test, set to bolster its U.S. market share and revenues. The company also completed supporting studies for Health Canada and expanded its Commercialisation Department, aiming to strengthen its North American presence. Despite these advancements, Medmira experienced a net loss of $590,789 this quarter, with a slight increase in working capital deficit.
For further insights into TSE:MIR stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money